Avenue Therapeutics, Inc. (ATXI): Price and Financial Metrics


Avenue Therapeutics, Inc. (ATXI): $1.10

0.04 (+3.77%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ATXI Stock Price Chart Interactive Chart >

Price chart for ATXI

ATXI Price/Volume Stats

Current price $1.10 52-week high $16.65
Prev. close $1.06 52-week low $0.98
Day low $1.07 Volume 47,700
Day high $1.11 Avg. volume 1,025,145
50-day MA $1.23 Dividend yield N/A
200-day MA $2.75 Market Cap 5.59M

Avenue Therapeutics, Inc. (ATXI) Company Bio


Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes an intravenous formulation of tramadol HCI principally for use in the acute/intensive care hospital setting. Its product candidate is IV Tramadol for the treatment of post-operative pain. The company was founded in 2015 and is based in New York, New York.


ATXI Latest News Stream


Event/Time News Detail
Loading, please wait...

ATXI Latest Social Stream


Loading social stream, please wait...

View Full ATXI Social Stream

Latest ATXI News From Around the Web

Below are the latest news stories about AVENUE THERAPEUTICS INC that investors may wish to consider to help them evaluate ATXI as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time for another breakdown of the biggest pre-market stock movers traders will want to know about on Thursday morning!

William White on InvestorPlace | March 9, 2023

Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates

Company to participate in Type C meeting for IV Tramadol with FDA on March 9, 2023MIAMI, March 08, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases, today announced that it will participate in a Type C meeting with the FDA on March 9, 2023 to discuss a proposed study protocol to assess the risk of respirat

Yahoo | March 8, 2023

Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy

AJ201 is being evaluated in a Phase 1b/2a clinical trial in the U.S. for the rare X-linked genetic neurodegenerative disease also known as Kennedy’s Disease which currently has no FDA approved therapyMIAMI, March 02, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases, today announced that it has entered into

Yahoo | March 2, 2023

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI)

Aegis Capital Corp.acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI).

Yahoo | January 31, 2023

Avenue Therapeutics Announces Closing of $3.25 Million Registered Direct and Private Placement

MIAMI, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, today announced the closing of its previously announced registered direct offering and concurrent private placement with a single institutional accredited investor. The Company issued 1,940,299 shares of common stock and pre-funded warran

Yahoo | January 31, 2023

Read More 'ATXI' Stories Here

ATXI Price Returns

1-mo -0.90%
3-mo -5.17%
6-mo -89.09%
1-year -85.73%
3-year -99.13%
5-year -98.37%
YTD -5.17%
2022 -91.48%
2021 -84.74%
2020 -38.02%
2019 77.78%
2018 49.17%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8142 seconds.